BioLineRx Doses First Patient for BKT-140/BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment

BioLineRx Doses First Patient for BKT-140/BL-8040’s Second Indication as Novel Stem Cell Mobilization Treatment

The results from the phase 1 trial expected by end of 2014 or early 2015. BKT-140/BL-8040 is also in the midst of a Phase 2 trial for AML, with results expected in early 2015.

September 3rd, 2014|Clinical Program BL8040, Recent News|

Patent issued in Japan covering the composition and use of novel chemokine binding polypeptides

Biokine Therapeutics Announces Issuance of Japan Patent covering the composition and use of novel chemokine binding polypeptides
capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).

July 1st, 2014|Pre-Clinical Programs, Recent News|